Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1927737
18 June 2024 11:34AM

CompuGroup Medical acquires AmbulApps


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Mergers & Acquisitions
CompuGroup Medical acquires AmbulApps

18.06.2024 / 11:34 CET/CEST
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical acquires AmbulApps  

Koblenz - CompuGroup Medical acquires AmbulApps GmbH, a specialist in digital anamnesis tools. Founded in Neuss in 2015, the company organizes, digitizes and structures the collection of data from and about patients. CompuGroup Medical will integrate AmbulApps' applications into its portfolio of solutions and further develop them.

AmbulApps offers solutions for digital patient information, anamnesis in the waiting room, home visits, the creation of treatment plans and the documentation of medical interventions. Data is stored in existing systems as documents and structured information. This reduces workload and optimizes information systems, especially in practices that were previously mostly paper-based. AmbulApp's many years of experience in the field of physician, clinic and document management software and a large network of partners form the basis for a powerful, legally compliant software solution.

"With the acquisition of AmbulApps, we once again underline our commitment to provide our customers in the healthcare sector with innovative technologies," explains Dr. Ulrich Thomé, Managing Director Ambulatory Information Systems DACH at CompuGroup Medical. "AmbulApps' expertise in digital anamnesis is a valuable addition and will be integrated into our existing solutions. This will enable our customers to further improve the effectiveness and efficiency of patient care," said Dr. Thomé.

"We are delighted to become part of CompuGroup Medical, one of the world's leading e-health companies. This will enable us to make AmbulApps' technology available to an even larger customer base and to further develop it," says Lars Schmidt, Managing Director of AmbulApps.



18.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1927737

 
End of News EQS News Service

1927737  18.06.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1927737&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.